Hussman Strategic Advisors Inc. Buys 42,000 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Hussman Strategic Advisors Inc. increased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 20.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 252,000 shares of the company’s stock after purchasing an additional 42,000 shares during the period. Hussman Strategic Advisors Inc. owned approximately 0.08% of Amneal Pharmaceuticals worth $1,996,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Handelsbanken Fonder AB bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $309,000. Convergence Investment Partners LLC increased its position in shares of Amneal Pharmaceuticals by 24.7% in the fourth quarter. Convergence Investment Partners LLC now owns 208,009 shares of the company’s stock worth $1,647,000 after purchasing an additional 41,161 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Amneal Pharmaceuticals by 24.1% in the fourth quarter. New York State Common Retirement Fund now owns 220,627 shares of the company’s stock worth $1,747,000 after purchasing an additional 42,909 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Amneal Pharmaceuticals by 9.3% in the fourth quarter. Principal Financial Group Inc. now owns 96,835 shares of the company’s stock worth $767,000 after purchasing an additional 8,213 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Amneal Pharmaceuticals by 3.5% in the fourth quarter. Rhumbline Advisers now owns 232,264 shares of the company’s stock worth $1,840,000 after purchasing an additional 7,875 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on AMRX. Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Insider Activity

In other news, Director Gautam Patel sold 80,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total transaction of $651,200.00. Following the completion of the sale, the director now owns 1,888,886 shares of the company’s stock, valued at approximately $15,375,532.04. This represents a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 160,000 shares of company stock valued at $1,292,000. 26.56% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $7.85 on Thursday. The firm has a market cap of $2.43 billion, a P/E ratio of -11.54 and a beta of 1.10. The stock has a 50 day simple moving average of $8.04 and a two-hundred day simple moving average of $8.27. Amneal Pharmaceuticals, Inc. has a 1 year low of $5.01 and a 1 year high of $9.48.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.